NYSE:RCUS - Arcus Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $47.64
  • Forecasted Upside: 29.69 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$36.73
▼ -0.25 (-0.68%)
1 month | 3 months | 12 months
Get New Arcus Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RCUS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RCUS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$47.64
▲ +29.69% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Arcus Biosciences in the last 3 months. The average price target is $47.64, with a high forecast of $70.00 and a low forecast of $34.00. The average price target represents a 29.69% upside from the last price of $36.73.
Buy
The current consensus among 9 contributing investment analysts is to buy stock in Arcus Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/30/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/28/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/26/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/25/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/21/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/20/2021BenchmarkBoost Price TargetBuy$32.00 ➝ $51.00Low
i
1/19/2021TruistBoost Price Target$45.00 ➝ $70.00Low
i
1/19/2021WedbushBoost Price TargetOutperform$48.00 ➝ $55.00Low
i
Rating by R. Driscoll at Wedbush
1/13/2021Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$39.00 ➝ $62.00Medium
i
11/24/2020Berenberg BankInitiated CoverageBuy$50.00 ➝ $50.00Medium
i
11/23/2020Evercore ISIInitiated CoverageOutperformHigh
i
11/6/2020SVB LeerinkLower Price TargetOutperform$44.00 ➝ $41.00Medium
i
Rating by Geoff Porges at SVB Leerink LLC
8/10/2020WedbushReiterated RatingOutperformLow
i
Rating by R. Driscoll at Wedbush
8/10/2020SVB LeerinkBoost Price TargetOutperform$42.00 ➝ $44.00High
i
Rating by Geoff Porges at SVB Leerink LLC
6/10/2020SunTrust BanksBoost Price TargetBuy$22.00 ➝ $45.00Low
i
6/2/2020CitigroupBoost Price Target$15.00 ➝ $41.00Low
i
5/29/2020SVB LeerinkReiterated RatingOutperform$21.00 ➝ $42.00High
i
5/27/2020WedbushBoost Price TargetOutperform$40.00 ➝ $48.00High
i
5/19/2020Cantor FitzgeraldReiterated RatingOverweightLow
i
Rating by A. Young at Cantor Fitzgerald
5/14/2020MizuhoBoost Price TargetBuy$22.00 ➝ $40.00High
i
Rating by Mara Goldstein at Mizuho
5/7/2020BarclaysReiterated RatingBuy$35.00High
i
5/6/2020WedbushBoost Price TargetOutperform$26.00 ➝ $40.00High
i
4/16/2020BTIG ResearchBoost Price Target$20.00 ➝ $34.00High
i
4/2/2020Cantor FitzgeraldInitiated CoverageOverweight$21.00High
i
4/1/2020SunTrust BanksBoost Price TargetBuy$20.00 ➝ $22.00High
i
3/4/2020BarclaysInitiated CoverageOverweight$24.00High
i
2/26/2020MizuhoReiterated RatingBuy$22.00Medium
i
Rating by Mara Goldstein at Mizuho
12/18/2019MizuhoInitiated CoverageBuy$22.00High
i
Rating by Mara Goldstein at Mizuho
11/12/2019SunTrust BanksInitiated CoverageBuy$20.00High
i
11/11/2019MizuhoReiterated RatingBuy$22.00Low
i
Rating by Mara Goldstein at Mizuho
10/20/2019MizuhoReiterated RatingBuyMedium
i
Rating by Mara Goldstein at Mizuho
9/26/2019MizuhoInitiated CoverageBuy$22.00High
i
6/5/2019CitigroupLower Price TargetBuy ➝ In-Line$25.00 ➝ $15.00Low
i
5/24/2019CitigroupReiterated RatingBuy ➝ Buy$25.00Low
i
5/3/2019SVB LeerinkReiterated RatingOutperformHigh
i
Rating by G. Porges at SVB Leerink LLC
3/18/2019BTIG ResearchInitiated CoverageBuy$20.00Low
i
10/9/2018WedbushInitiated CoverageOutperform ➝ Outperform$22.00High
i
Rating by R. Driscoll at Wedbush
4/9/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$21.00High
i
Rating by G. Porges at SVB Leerink LLC
4/9/2018CitigroupInitiated CoverageBuy ➝ Buy$18.00High
i
4/9/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$18.00High
i
(Data available from 1/20/2016 forward)
Arcus Biosciences logo
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer therapies in the United States. The company's product pipeline includes, AB928, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 monoclonal antibody that is in Phase Ib clinical trial for monotherapy. It is also developing AB154, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab and AB928; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. Arcus Biosciences, Inc. has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab (AB154), its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; license agreements with Taiho Pharmaceutical Co., Ltd and Abmuno Therapeutics LLC; and strategic relationship with WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was founded in 2015 and is based in Hayward, California.
Read More

Today's Range

Now: $36.73
$36.00
$38.44

50 Day Range

MA: $30.51
$25.96
$38.83

52 Week Range

Now: $36.73
$8.55
$40.01

Volume

469,459 shs

Average Volume

626,260 shs

Market Capitalization

$2.38 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Frequently Asked Questions

What sell-side analysts currently cover shares of Arcus Biosciences?

The following Wall Street sell-side analysts have issued stock ratings on Arcus Biosciences in the last twelve months: Barclays PLC, Berenberg Bank, BTIG Research, Cantor Fitzgerald, Citigroup Inc., Evercore ISI, Mizuho, SunTrust Banks, Inc., SVB Leerink LLC, Truist, Wedbush, and Zacks Investment Research.

What is the current price target for Arcus Biosciences?

10 Wall Street analysts have set twelve-month price targets for Arcus Biosciences in the last year. Their average twelve-month price target is $47.30, suggesting a possible upside of 28.8%. Truist has the highest price target set, predicting RCUS will reach $70.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $34.00 for Arcus Biosciences in the next year.

What is the current consensus analyst rating for Arcus Biosciences?

Arcus Biosciences currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RCUS will outperform the market and that investors should add to their positions of Arcus Biosciences.

What other companies compete with Arcus Biosciences?

How do I contact Arcus Biosciences' investor relations team?

Arcus Biosciences' physical mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company's listed phone number is 510-694-6200 and its investor relations email address is investorinfo@arcusbio.com. The official website for Arcus Biosciences is www.arcusbio.com.